The controversy over homocysteine and cardiovascular risk

American Journal of Clinical Nutrition

Volumn 72, Issue 2, 2000, Pages 324-332

  Ueland, P M ^a   Refsum, H ^a   Beresford, S A A ^a   Vollset, S E ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

Cardiovascular disease; Homocysteine; Methylene tetrahydrofolate reductase polymorphism; Nephrosclerosis; Renal

Indexed keywords

HOMOCYSTEINE;

ADULT; AMINO ACID BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DISEASE ASSOCIATION; ETHNOLOGY; GENOTYPE; HUMAN; IN VIVO STUDY; META ANALYSIS; NEPHROSCLEROSIS; REVIEW; RISK FACTOR;

EID: 0033878934     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/72.2.324     Document Type: Review

References (121)

1. Disorder of transsulfuration
2. Homocysteine and vascular disease
3. The pathogenesis of coronary artery disease. A possible role for methionine metabolism
4. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: Framingham Study
5. Plasma homocysteine, a risk factor for vascular disease: Plasma levels in health, disease, and drug therapy
6. Homocysteine and cardiovascular disease
7. Hyperhomocysteinemia and venous thrombosis: A meta-analysis
8. Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence
9. Homocysteine and ischemic heart disease: Results of a prospective study with implications regarding prevention
10. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: The result of a metaanalysis
11. Plasma homocysteine and coronary heart disease: Systematic review of published epidemiological studies
12. A common methylenetetrahydrofolate reductase gene mutation and longevity
13. Methylenetetrahydrofolate reductase (MTHFR) mutation, homocyst(e)ine, and coronary artery disease
14. Common mutation in the methylenetetrahydrofolate reductase gene offers no support for mild hyperhomocysteinemia being a causal risk factor for cardiovascular disease
15. Recent data are not in conflict with homocysteine as a cardiovascular risk factor
16. A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians
17. Nonfasting plasma total homocysteine level and mortality in middle-aged and elderly men and women in Jerusalem
18. Hyperhomocysteinemia in chronic renal disease
19. Plasma homocysteine levels and mortality in patients with coronary artery disease
20. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease
21. Plasma homocysteine concentration predicts mortality in noninsulin-dependent diabetic patients with and without albuminuria
22. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus
23. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism
24. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: A 10-year follow-up
25. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes
26. Homocysteine, folic acid and cardiovascular disease risk
27. Quantitative methods in the review of epidemiologic literature
28. Meta-analysis, decision-analysis, and cost-effectiveness analysis
29. Homocysteine and coronary risk in the general population: Analysis from the Scottish Heart Health Study and Scottish MONICA surveys
30. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study
31. Serum total homocysteine and coronary heart disease
32. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women
33. Homocysteine and shortterm risk of myocardial infarction and stroke in the elderly: Rotterdam Study
34. Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial
35. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: Atherosclerosis Risk in Communities (ARIC) study
36. Homocysteine and risk of cardiovascular disease among postmenopausal women
37. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians
38. Homocysteine and ischaemic heart disease in the Caerphilly cohort
39. Serum total homocysteine and coronary heart disease: Prospective study in middle aged men
40. Relation of total homocysteine and lipid levels in children to premature cardiovascular death in male relatives
41. Association between plasma total homocysteine and parental history of cardiovascular disease in children with familial hypercholesterolemia
42. Plasma homocysteine distribution and its association with parental history of coronary artery disease in black and white children: The Bogalusa Heart Study
43. The C677T mutation in the methylenetetrahydrofolate reductase gene predisposes to hyperhomocysteinemia in children with familial hypercholesterolemia treated with cholestyramine
44. Plasma homocysteine as a risk factor for vascular disease. The European concerted action project
45. Plasma total homocysteine levels in patients with early-onset coronary heart disease and a low cardiovascular risk profile
46. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism
47. Coexistence of antithrombin deficiency, factor V Leiden and hyperhomocysteinemia in a thrombotic family
48. Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: Metabolic significance, risks and impact on folate requirement
49. The structure and properties of methylenetetrahydrofolate reductase from Escherichia coli suggest how folate ameliorates human hyperhomocysteinemia
50. Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (≥40 μmol/liter). The Hordaland homocysteine study
51. The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase geno-types
52. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease
53. MTHFR association with arteriosclerotic vascular disease?
54. Methylenetetrahydrofolate reductase C677T mutation, plasma homocysteine, and folate in subjects from northern Italy with or without angiographically documented severe coronary atherosclerotic disease: Evidence for an important genetic-environmental interaction
55. Relationship between total plasma homocysteine, polymorphisms of homocysteine metabolism related enzymes, risk factors and coronary artery disease in the Australian hospital-based population
56. Methylene tetrahydrofolate reductase genotype and the risk and extent of coronary artery disease in a population with low plasma folate
57. Analysis of the 677 C T mutation of the methylenetetrahydrofolate reductase gene in different ethnic groups
58. Worldwide distribution of a common methylenetetrahydrofolate reductase mutation
59. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease
60. Molecular variant of 5,10-methylenetetrahydrofolate reductase risk factor of ischemic heart disease in the Japanese population
61. Association of methylenetetrahydrofolate reductase gene polymorphism with carotid arterial wall thickening and myocardial infarction risk in NIDDM
62. Methylenetetrahydrofolate reductase and apolipoprotein E polymorphisms are independent risk factors for coronary heart disease in Japanese: A case-control study
63. Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke in Japanese
64. Evaluation of genetic risk factors for silent brain infarction
65. The TT genotype of the methylenetetrahydrofolate reductase C677T gene polymorphism is associated with the extent of coronary atherosclerosis in patients at high risk for coronary artery disease
66. Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial infarction in young males
67. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: Prevalence and risk assessment
68. Additional genetic risk factors for venous thromboembolism in carriers of the factor V Leiden mutation
69. The G20210A mutation of the prothrombin gene in patients with previous first episodes of deep-vein thrombosis: Prevalence and association with factor V G1691A, methylenetetrahydrofolate reductase C677T and plasma prothrombin levels
70. Effect of the MTHFRC677T variant on risk of venous thromboembolism: Interaction with factor V Leiden and prothrombin (F2G20210A) mutations
71. MTHFR polymorphism, methyl-replete diets and the risk of colorectal carcinoma and adenoma among U.S. men and women: An example of gene-environment interactions in colorectal tumorigenesis
72. Multivitamin use, folate, and colon cancer in women in the Nurses' Health Study
73. Opposite effects of plasma homocysteine and the methylenetetrahydrofolate reductase C677T mutation on carotid artery geometry in asymptomatic adults
74. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke
75. Serum folate and risk for ischemic stroke. First National Health and Nutrition Examination Survey epidemiologic follow-up study
76. Serum folate and risk of fatal coronary heart disease
77. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women
78. Major lifestyle determinants of plasma total homocysteine distribution: The Hordaland Homocysteine Study
79. Serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey (1991-1994): Population reference ranges and contribution of vitamin status to high serum concentrations
80. Pro-thrombotic effects of a folic acid deficient diet in rat platelets and macrophages related to elevated homocysteine and decreased n-3 polyunsaturated fatty acids
81. Endpoints for homocysteine-lowering trials
82. Vitamins and progression of atherosclerosis in hyper-homocyst(e)inaemia
83. Normohomocysteinaemia and vitamin-treated hyperhomocysteinaemia are associated with similar risks of cardiovascular events in patients with premature peripheral arterial occlusive disease. A prospective cohort study
84. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: A randomised, placebocontrolled trial
85. Combination of low-dose folic acid and pyridoxine for treatment of hyperhomocysteinaemia in patients with premature arterial disease and their relatives
86. Hyperhomocysteinemia and low pyridoxal phosphate: Common and independent reversible risk factors for coronary artery disease
87. Carotid atherosclerosis measured by B-mode ultrasound in populations: Associations with cardiovascular risk factors in the ARIC study
88. Carotidartery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study
89. Association between elevated plasma total homocysteine and increased common carotid artery wall thickness
90. Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. The Perth Carotid Ultrasound Disease Assessment Study (CUDAS)
91. Homocysteine, atherosclerosis and prevalent cardiovascular disease in the elderly: The Rotterdam Study
92. Association between plasma homocysteine concentration and carotid atherosclerosis in hemodialysis patients
93. Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects
94. The natural history of vascular disease in homocystinuria and the effects of treatment
95. Homocystinuria due to cystathionine betasynthase deficiency in Ireland: 25 years' experience of a newborn screened and treated population with reference to clinical outcome and biochemical control
96. Coexistence of hereditary homocystinuria and factor V Leiden - Effect on thrombosis
97. Thrombophilia, homocystinuria, and mutation of the factor V gene
98. Homozygous cystathionine beta-synthase deficiency, combined with factor V Leiden or thermolabile methylenetetrahydrofolate reductase in the risk of venous thrombosis
99. Factor V Leiden (Arg506Gln), a confounding genetic risk factor but not mandatory for the occurrence of venous thromboembolism in homozygotes and obligate heterozygotes for cystathionine beta-synthase deficiency
100. Mechanisms of thrombosis in hyperhomocysteinemia
101. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo
102. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults
103. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: An effect reversible with vitamin C therapy
104. Endothelial dysfunction by acute hyperhomocyst(e)inaemia: Restoration by folic acid
105. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans
106. Oral folate enhances endothelial function in hyperhomocysteinaemic subjects
107. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction
108. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women
109. Role of nitric oxide in cardiovascular disease: Focus on the endothelium
110. Arterial endothelial dysfunction related to passive smoking is potentially reversible in healthy young adults
111. Vascular reactivity
112. Homocysteinemia and endothelial damage after methionine load
113. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins
114. Total plasma homocysteine and cardiovascular risk profile. The Hordaland homocysteine study
115. Hyperhomocysteinemia in end-stage renal disease (ESRD): Prevalence, etiology, and potential relationship to arteriesclerotic outcomes
116. Homocysteine: 'Expensive creatinine,' or important, modifiable risk factor for arteriosclerotic outcomes in renal transplant recipients?
117. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable transplant recipients: A prospective study
118. Plasma homocysteine in acute myocardial infarction: Homocysteine-lowering effect of folic acid
119. Homocysteine metabolism and risk of myocardial infarction: Relation with vitamins B-6, B-12, and folate
120. Serial measures of plasma homocyst(e)ine after acute myocardial infarction